Reversibility of Immune Dysfunction Following Pediatric Thermal Injury

Area of Science:

• Immunology
• Pediatric Burn Injury
• Infectious Diseases

Background:

• Pediatric thermal injury leads to immune dysfunction, increasing the risk of nosocomial infections (NI).
• Identifying at-risk pediatric burn patients and developing immunomodulatory therapies are critical for improving outcomes.
• Understanding immune response post-burn is crucial for preventing secondary complications.

Purpose of the Study:

• To investigate immune dysfunction in pediatric burn patients who develop NI.
• To evaluate the ex-vivo reversibility of immune suppression using specific immunomodulators.
• To identify biomarkers for predicting NI risk and potential therapeutic targets.

Main Methods:

• Analysis of immune function in 141 pediatric burn patients, comparing those who developed NI with those who did not.
• Measurement of ex-vivo lipopolysaccharide (LPS)-induced tumor necrosis factor alpha (TNFα) and phytohemagglutinin (PHA)-induced interleukin (IL)-10 production.
• Assessment of immune cell ratios (TNFα/CD14+ monocytes, IL-10/CD4+ lymphocytes) and ex-vivo treatment with GM-CSF and varlilumab.

Main Results:

• Patients developing NI showed decreased innate (LPS-induced TNFα) and adaptive (PHA-induced IL-10) immune function.
• Specific immune cell ratios (LPS-TNFα/CD14+, PHA-IL-10/CD4+) were significantly lower in patients who developed NI.
• GM-CSF increased ex-vivo TNFα production, while varlilumab enhanced IL-10 production, suggesting potential for immune restoration.

Conclusions:

• Key immune markers can identify pediatric burn patients at higher risk for NI.
• Recombinant human granulocyte macrophage-colony stimulating factor (GM-CSF) and varlilumab show potential as ex-vivo immunomodulators to restore immune function post-burn.
• Early intervention with immunomodulators may mitigate immune suppression and reduce NI incidence in pediatric burn patients.